The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Pirmgrel     6-(1,8- diazabicyclo[4.3.0]nona- 2,4,6,8...

Synonyms: PIRMAGREL, Pirmagrelum, CHEMBL48092, SureCN636018, CGS-13080, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of PIRMAGREL


High impact information on PIRMAGREL


Biological context of PIRMAGREL


Anatomical context of PIRMAGREL


Associations of PIRMAGREL with other chemical compounds


Gene context of PIRMAGREL


Analytical, diagnostic and therapeutic context of PIRMAGREL

  • Greater attenuation of TxB2 was found after treatment with the drug combination (P less than .01 from vehicle, P less than .05 from CGS-13080 alone) [4].
  • No adverse hemodynamic or other effects attributable to CGS-13080 occurred during or immediately following cardiopulmonary bypass [19].
  • The control group was fed a standard pellet diet, while the treated groups were fed the standard diet supplemented with either a low dose (0.8 g per 10 kg pellet) or a high dose (1.6 g per 10 kg pellet) of CGS 13080 [20].
  • The effect of a thromboxane A2 synthetase inhibitor (CGS-13080) on canine intestine was studied using a single dose of radiation, and radioactive microspheres were used to determine resultant blood flow [21].


  1. Potentiation of myocardial salvage by tissue type plasminogen activator in combination with a thromboxane synthetase inhibitor in ischemic cat myocardium. Lefer, A.M., Mentley, R., Sun, J.Z. Circ. Res. (1988) [Pubmed]
  2. Chronic thromboxane synthase inhibition with CGS 12970 in human cyclosporine nephrotoxicity. Smith, S.R., Kubacki, V.B., Rakhit, A., Martin, L.L., Schaffer, A.V., Jasani, M.K., Hefty, D.J., Johnston, T., Cannon, C., Bennett, W.M. Transplantation (1993) [Pubmed]
  3. Comparison of the effects of a thromboxane synthase inhibitor or prostacyclin in combination with a phosphodiesterase inhibitor for prevention of experimental thrombosis and sudden death in rabbits. Smith, E.F., Egan, J.W. J. Pharmacol. Exp. Ther. (1987) [Pubmed]
  4. Potentiation of the protective effects of a converting enzyme inhibitor and a thromboxane synthetase inhibitor in hemorrhagic shock. Bitterman, H., Phillips, G.R., Dragon, G., Lefer, A.M. J. Pharmacol. Exp. Ther. (1987) [Pubmed]
  5. Fetal and maternal response to intravenous infusion of a thromboxane synthetase inhibitor. Cardin, J.P., Ross, M.G., Ervin, M.G., Schaffer, A.V., Douglas, F.L., Simke, J.P. Am. J. Obstet. Gynecol. (1990) [Pubmed]
  6. Effects of CGS-13080, a thromboxane inhibitor, on pulmonary vascular resistance in patients after mitral valve replacement surgery. Kim, Y.D., Foegh, M.L., Wallace, R.B., Ng, L., Ahmed, S.W., Katz, N.M., Siegelman, R., Franco, K., Douglas, F., Ku, E. Circulation (1988) [Pubmed]
  7. Selective and nonselective inhibition of thromboxane formation. FitzGerald, G.A., Oates, J.A. Clin. Pharmacol. Ther. (1984) [Pubmed]
  8. Intrathoracic platelet accumulation in the guinea-pig induced by intravenous administration of arachidonic acid--effect of cyclooxygenase and thromboxane synthetase inhibitors. Barrett, P.A., Butler, K.D., Shand, R.A., Wallis, R.B. Thromb. Haemost. (1986) [Pubmed]
  9. Differential antagonism of airway contractile responses to prostaglandin (PG)D2 and 9 alpha, 11 beta-PGF2 by atropine, SK&F 88046 and SQ 29,548 in the guinea pig. Underwood, D.C., Muccitelli, R.M., Luttmann, M.A., Hay, D.W., Torphy, T.J., Wasserman, M.A. J. Pharmacol. Exp. Ther. (1994) [Pubmed]
  10. Preliminary observations of the acute effects of selective serum thromboxane inhibition and angiotensin converting enzyme inhibition on blood pressure and renal hemodynamics in hypertensive humans. Weir, M.R., Klassen, D.K., Hoover, N., Douglas, F.L. Journal of clinical pharmacology. (1989) [Pubmed]
  11. Influence of selective thromboxane synthetase blocker CGS-13080 on thromboxane and prostacyclin biosynthesis in whole blood: evidence for synthesis of prostacyclin by leukocytes from platelet-derived endoperoxides. Mehta, J., Mehta, P., Lawson, D.L., Ostrowski, N., Brigmon, L. J. Lab. Clin. Med. (1985) [Pubmed]
  12. Effects of a 48 hour continuous intravenous infusion of CGS 13080-primagrel, a selective thromboxane synthetase inhibitor, on the perinatal and early postnatal period in the guinea pig. Keith, J., Rowles, T., Warwick, K., Yau, E. Teratology (1992) [Pubmed]
  13. Output and effects of thromboxane produced by the liver perfused with phorbol myristate acetate. Tran-Thi, T.A., Gyufko, K., Reinke, M., Decker, K. Biol. Chem. Hoppe-Seyler (1988) [Pubmed]
  14. Interaction between thromboxane A2 and angiotensin II in postischemic renal vasoconstriction in dogs. Abels, B.C., Branch, R.A., Sabra, R. J. Pharmacol. Exp. Ther. (1993) [Pubmed]
  15. Comparison of thromboxane synthetase inhibitor and methylprednisolone effects on protamine responses in dogs. Fomsgaard, J.S., Kim, Y.D., Burke, T.A., Viswanathan, T., Schaffer, A.V., Peppard, J., Douglas, F.L., Danchak, M., Myers, A.K. Anesth. Analg. (1992) [Pubmed]
  16. Protection of ischemic cat myocardium by CGS-13080, a selective potent thromboxane A2 synthesis inhibitor. Burke, S.E., DiCola, G., Lefer, A.M. J. Cardiovasc. Pharmacol. (1983) [Pubmed]
  17. Pathophysiological mechanisms of sudden death induced by platelet activating factor. Lefer, A.M., Müller, H.F., Smith, J.B. Br. J. Pharmacol. (1984) [Pubmed]
  18. Effect of thromboxane synthase inhibition on the thrombolytic action of tissue-type plasminogen activator in a rabbit model of peripheral arterial thrombosis. Shebuski, R.J., Storer, B.L., Fujita, T. Thromb. Res. (1988) [Pubmed]
  19. Pharmacological, hematological, and physiological effects of a new thromboxane synthetase inhibitor (CGS-13080) during cardiopulmonary bypass in dogs. DeCampli, W.M., Goodwin, D., Kosek, J.C., Handen, C.E., Mitchell, R.S., Miller, D.C. Ann. Thorac. Surg. (1986) [Pubmed]
  20. Suppression of S-antigen-induced experimental autoimmune uveoretinitis in Lewis rats by oral administration with CGS-13080, a thromboxane synthetase inhibitor. Li, Q., Lopez, J.S., Caspi, R.R., Roberge, F.G., Nussenblatt, R.B., Kador, P.F., Chan, C.C. Exp. Eye Res. (1993) [Pubmed]
  21. Lack of protective effect of thromboxane synthetase inhibitor (CGS-13080) on single dose radiated canine intestine. Barter, J.F., Marlow, D., Kamath, R.K., Harbert, J., Torrisi, J.R., Barnes, W.A., Potkul, R.K., Newsome, J.T., Delgado, G. Gynecol. Oncol. (1991) [Pubmed]
WikiGenes - Universities